Search Results - "Callaghan, John T"

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy by Crews, Kristine R., Monte, Andrew A., Huddart, Rachel, Caudle, Kelly E., Kharasch, Evan D., Gaedigk, Andrea, Dunnenberger, Henry M., Leeder, J. Steven, Callaghan, John T., Samer, Caroline Flora, Klein, Teri E., Haidar, Cyrine E., Van Driest, Sara L., Ruano, Gualberto, Sangkuhl, Katrin, Cavallari, Larisa H., Müller, Daniel J., Prows, Cynthia A., Nagy, Mohamed, Somogyi, Andrew A., Skaar, Todd C.

“…Opioids are mainly used to treat both acute and chronic pain. Several opioids are metabolized to some extent by CYP2D6 (codeine, tramadol, hydrocodone,…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Update by Karnes, Jason H., Rettie, Allan E., Somogyi, Andrew A., Huddart, Rachel, Fohner, Alison E., Formea, Christine M., Ta Michael Lee, Ming, Llerena, Adrian, Whirl‐Carrillo, Michelle, Klein, Teri E., Phillips, Elizabeth J., Mintzer, Scott, Gaedigk, Andrea, Caudle, Kelly E., Callaghan, John T.

“…Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in…”
Get full text

Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial by Fulton, Cathy R, Zang, Yong, Desta, Zeruesenay, Rosenman, Marc B, Holmes, Ann M, Decker, Brian S, Zhang, Yifei, T Callaghan, John, Pratt, Victoria M, Levy, Kenneth D, Gufford, Brandon T, Dexter, Paul R, Skaar, Todd C, Eadon, Michael T

“…Tramadol and codeine are metabolized by CYP2D6 and are subject to drug-gene and drug-drug interactions. This interim analysis examined prescribing behavior and…”
Get full text

THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE by BJORNSSON, Thorir D, CALLAGHAN, John T, KUMAR, Gondi, MCLEOD, James, OBACH, R. Scott, ROBERTS, Stanley, ROE, Amy, SHAH, Anita, SNIKERIS, Fred, SULLIVAN, John T, TWEEDIE, Donald, VEGA, Jose M, EINOLF, Heidi J, WALSH, John, WRIGHTON, Steven A, FISCHER, Volker, GAN, Lawrence, GRIMM, Scott, KAO, John, KING, S. Peter, MIWA, Gerald, LAN NI

“…Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies. There is a common desire by…”
Get full text

Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer by Rowe, Elizabeth J, Shugg, Tyler, Ly, Reynold C, Philips, Santosh, Rosenman, Marc B, Callaghan, John T, Radovich, Milan, Overholser, Brian R, Schneider, Bryan P, Tisdale, James E, Skaar, Todd C

“…Drug-induced prolongation of the heart rate-corrected QT interval (QTc) is associated with increased risk for the potentially fatal arrhythmia torsades de…”
Get full text

Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers by Metzger, Ingrid F., PhD, Quigg, Troy C., MD, Epstein, Noam, Aregbe, Abdulateef O., MD, Thong, Nancy, Callaghan, John T., MD, PhD, Flockhart, David A., MD, PhD, Nguyen, Anne T, Stevens, Colleen K, Gupta, Samir K, Desta, Zeruesenay, PhD

“…Abstract Background Efavirenz exhibits multiple interactions with drug-metabolizing enzymes and transporters, and for this reason efavirenz-based HIV therapy…”
Get full text

Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned by Shugg, Tyler, Tillman, Emma M., Breman, Amy M., Hodge, Jennelle C., McDonald, Christine A., Ly, Reynold C., Rowe, Elizabeth J., Osei, Wilberforce, Smith, Tayler B., Schwartz, Peter H., Callaghan, John T., Pratt, Victoria M., Lynch, Sheryl, Eadon, Michael T., Skaar, Todd C.

“…In 2019, Indiana University launched the Precision Health Initiative to enhance the institutional adoption of precision medicine, including pharmacogenetics…”
Get full text

The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial by Eadon, Michael T., Rosenman, Marc B., Zhang, Pengyue, Fulton, Cathy R., Callaghan, John T., Holmes, Ann M., Levy, Kenneth D., Gupta, Samir K., Haas, David M., Vuppalanchi, Raj, Benson, Eric A., Kreutz, Rolf P., Tillman, Emma M., Shugg, Tyler, Pierson, Rebecca C., Gufford, Brandon T., Pratt, Victoria M., Zang, Yong, Desta, Zeruesenay, Dexter, Paul R., Skaar, Todd C.

“…Adverse drug events (ADEs) account for a significant mortality, morbidity, and cost burden. Pharmacogenetic testing has the potential to reduce ADEs and…”
Get full text

Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee by Vassy, Jason L., Stone, Annjanette, Callaghan, John T., Mendes, Margaret, Meyer, Laurence J., Pratt, Victoria M., Przygodzki, Ronald M., Scheuner, Maren T., Wang-Rodriguez, Jessica, Schichman, Steven A.

“…Purpose The Veterans Health Administration (VHA) Clinical Pharmacogenetics Subcommittee is charged with making recommendations about whether specific…”
Get full text

Alcohol Consumption and Risk of Coronary Artery Disease (from the Million Veteran Program) by Song, Rebecca J., Nguyen, Xuan-Mai T., Quaden, Rachel, Ho, Yuk-Lam, Justice, Amy C., Gagnon, David R., Cho, Kelly, O'Donnell, Christopher J., Concato, John, Gaziano, J. Michael, Djoussé, Luc, Halasz, Ildiko, Federman, Daniel, Beckham, Jean, Sherman, Scott E., Sriram, Peruvemba, Tsao, Philip S., Boyko, Edward J., Xu, Junzhe, Lederle, Frank, Dellitalia, Louis J., McArdle, Rachel, Kaminsky, Laurence, Swann, Alan C., Hamner, Mark B., Florez, Hermes J., Pandya, Prashant, Villarreal, Gerardo, Wilson, Peter, Morgan, Timothy R., Davis, Lori, Hurley, Robin A., Meyer, Laurence, Ahuja, Sunil K., Konicki, Eric P., Cohen, David, Lichy, Jack, Whittle, Jeffrey, Haddock, Kathlyn Sue, Straub, Karl D., Callaghan, John T., Aguayo, Samuel M., Gupta, Samir, Washburn, Ronald G., Oehlert, Mary E., Hung, Adriana M., Wallbom, Agnes, Keith, Robert, Sonel, Elif, Schifman, Ronald B., Childress, Richard D., Godschalk, Michael F., Shuldiner, Alan R., Rastogi, Padmashri, Gutierrez, Salvador, Fernando, Ronald, Iruvanti, Pran R., Jhala, Darshana, Rosado-Rodriguez, Carlos, Mastorides, Stephen M., Harley, John B., Mattocks, Kristin, Robey, Brooks, Striker, Robert T., Rauchman, Michael, Wells, John, Ballas, Zuhair K., Woods, Susan S., Yeh, Shing Shing, Ratcliffe, Nora R., Klein, Jon B., Golden, Adam G., Ginzburg, Harold M., Sharma, Satish, Oursler, Kris Ann K., Whooley, Mary A., Gibson, Gretchen, Heinz

“…Moderate alcohol consumption has been associated with a lower risk of coronary artery disease (CAD) in the general population but has not been well studied in…”
Get full text

PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics by McDonagh, Ellen M, Thorn, Caroline F, Callaghan, John T, Altman, Russ B, Klein, Teri E

Get full text

Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers by Desta, Zeruesenay, Metzger, Ingrid F, Thong, Nancy, Lu, Jessica B L, Callaghan, John T, Skaar, Todd C, Flockhart, David A, Galinsky, Raymond E

“…Cytochrome P450 2B6 (CYP2B6) metabolizes clinically important drugs and other compounds. Its expression and activity vary widely among individuals, but…”
Get full text

Response to Gammal et al by Vassy, Jason L., Stone, Annjanette, Callaghan, John T., Mendes, Margaret, Meyer, Laurence J., Pratt, Victoria M., Przygodzki, Ronald M., Scheuner, Maren T., Wang-Rodriguez, Jessica, Schichman, Steven A.

Get full text

Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the IGNITE ADOPT PGx investigators by Skaar, Todd C., Myers, Rachel A., Fillingim, Roger B., Callaghan, John T., Cicali, Emily, Eadon, Michael T., Elwood, Erica N., Ginsburg, Geoffrey S., Lynch, Sheryl, Nguyen, Khoa A., Obeng, Aniwaa Owusu, Park, Haesuk, Pratt, Victoria M., Rosenman, Marc, Sadeghpour, Azita, Shuman, Saskia, Singh, Rajbir, Tillman, Emma M., Volpi, Simona, Wiisanen, Kristin, Winterstein, Almut G., Horowitz, Carol R., Voora, Deepak, Orlando, Lori, Chakraborty, Hrishikesh, Van Driest, Sara, Peterson, Josh F., Cavallari, Larisa A., Johnson, Julie A., Dexter, Paul R.

“…Chronic pain is a prevalent condition with enormous economic burden. Opioids such as tramadol, codeine, and hydrocodone are commonly used to treat chronic…”
Get full text

Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers by Shugg, Tyler, Ly, Reynold C, Rowe, Elizabeth J, Philips, Santosh, Hyder, Mustafa A, Radovich, Milan, Rosenman, Marc B, Pratt, Victoria M, Callaghan, John T, Desta, Zeruesenay, Schneider, Bryan P, Skaar, Todd C

“…Precision medicine approaches, including germline pharmacogenetics (PGx) and management of drug-drug interactions (DDIs), are likely to benefit patients with…”
Get more information

A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies by FOROUZESH, Bahram, TAKIMOTO, Chris H, ROWINSKY, Eric K, GOETZ, Andrew, DIAB, Sami, HAMMOND, Lisa A, SMETZER, Leslie, SCHWARTZ, Garry, GAZAK, Robert, CALLAGHAN, John T, VON HOFF, Daniel D

“…Purpose: This study was conducted to assess the feasibility of administering the oral diarylsulfonylurea (DSU) ILX-295501 on a weekly for 3 weeks every 4-week…”
Get full text

The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective by Bjornsson, Thorir D., Callaghan, John T., Einolf, Heidi J., Fischer, Volker, Gan, Lawrence, Grimm, Scott, Kao, John, King, S. Peter, Miwa, Gerald, Ni, Lan, Kumar, Gondi, McLeod, James, Obach, Scott R., Roberts, Stanley, Roe, Amy, Shah, Anita, Snikeris, Fred, Sullivan, John T., Tweedie, Donald, Vega, Jose M., Walsh, John, Wrighton, Steven A.

“…Current regulatory guidances do not address specific study designs for in vitro and in vivo drug‐drug interaction studies. There is a common desire by…”
Get full text

The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective by Bjornsson, Thorir D, Callaghan, John T, Einolf, Heidi J, Fischer, Volker, Gan, Lawrence, Grimm, Scott, Kao, John, King, S Peter, Miwa, Gerald, Ni, Lan, Kumar, Gondi, McLeod, James, Obach, Scott R, Roberts, Stanley, Roe, Amy, Shah, Anita, Snikeris, Fred, Sullivan, John T, Tweedie, Donald, Vega, Jose M, Walsh, John, Wrighton, Steven A

“…Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies. Thereisa common desire by regulatory…”
Get full text

The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity by Belle, Donna J., Callaghan, John T., Gorski, J. Christopher, Maya, Juan F., Mousa, Omiema, Wrighton, Steven A., Hall, Stephen D.

“…Aims  To examine the effects of an oral contraceptive containing ethinyloestradiol and norgestrel on intestinal and hepatic CYP3A activity using midazolam as a…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy by Crews, Kristine R., Monte, Andrew A., Huddart, Rachel, Caudle, Kelly E., Kharasch, Evan D., Gaedigk, Andrea, Dunnenberger, Henry M., Leeder, J. Steven, Callaghan, John T., Samer, Caroline Flora, Klein, Teri E., Haidar, Cyrine E., Van Driest, Sara L., Ruano, Gualberto, Sangkuhl, Katrin, Cavallari, Larisa H., Müller, Daniel J., Prows, Cynthia A., Nagy, Mohamed, Somogyi, Andrew A., Skaar, Todd C.

“…Opioids are mainly used to treat both acute and chronic pain. Several opioids are metabolized to some extent by CYP2D6 (codeine, tramadol, hydrocodone,…”
Get full text